PARP1 and ovarian carcinoma: Recently, poly ADP-ribose Polymerase (PARP) inhibitors have changed the treatment paradigm for ovarian cancer that can significantly improve the PFI, and finally prolonged the overall survival of patients with BRCA mutation [3–6].